NovLead Biotech Secures Hundreds of Millions in Series C Funding to Accelerate Global Expansion and Diversified Product Portfolio

VCBeat has exclusively learned that,Recently,Nanjing Noliving Biotechnology Co., Ltd. (hereinafter referred to as “Noliving Biotech”)completed hundreds of millions of yuan inCround of financing. This round of financing was led byDNTcapitalLead Investor,Yangzhou Guojin Group, Zhongshan Financial Holdings, Triwise Capital, Efung CapitalandXingxiangCapitaland other well-known institutions jointly participated in the investment.

The funds obtained will be used for the company’s first blockbuster product.“PortableNOInhalation Therapy Device”ofCapacity Expansion,Commercial promotion and overseas expansion, with accelerated follow-up“Centered onNOSustained-Release and Occurrence Technologies”Continuous Implementation of the Innovative Pipeline.Xiqiao CapitalServed as the exclusive financial advisor for this round of financing.

Noliving Biotech is an innovative medical device company specializing in gas-based diagnostics and therapeutics, recognized as the first of its kind in China and a global leader. The company boasts a team of top-tier, experienced technical and product development professionals, and possesses a molecular technology platform with international leading standards and independent core patents. Leveraging deep expertise across interdisciplinary fields such as chemistry, mechanics, materials science, algorithms, and sensing, Noliving Biotech has not only delivered more breakthrough diagnostic and therapeutic solutions for critical care and chronic diseases but also successfully explored diverse product application scenarios in the pet care and consumer sectors.

As a life-saving gas, nitric oxide (NO) can rapidly improve patients' oxygenation index and reduce pulmonary vascular resistance. It is widely used in clinical scenarios such as the treatment of critical conditions with high mortality rates, including pulmonary hypertension and hypoxemic respiratory failure, as well as perioperative life support. In China, due to constraints such as the bulky size of traditional industrial NO steel cylinders and limited gas sources, there has long been a situation where patients urgently require NO therapy but have no access to it.

The company’s first blockbuster product, the “Portable Inhaled Nitric Oxide (NO) Therapy Device,” addresses existing clinical pain points by completely eliminating the need for traditional gas cylinders. It fills a gap in China’s market for portable medical NO gas therapy devices and enables “instant, stable generation” of NO, making hospital-based NO gas therapy more compliant, safer, more convenient, and more effective.Following regulatory approval, the company’s product rapidly gained adoption in hundreds of hospitals both domestically and internationally, leveraging its distinct advantages in convenience, safety, and efficacy.Applied across numerous departments, including neonatal ICUs, adult ICUs, and cardiac surgery units, it has gained recognition from many clinical experts and delivered tangible benefits to patients.

In June and July 2024, two expert consensus statements on nitric oxide were simultaneously released in China: the "Expert Consensus on the Clinical Application of Inhaled Nitric Oxide Therapy in Acute and Critical Care," led by the Emergency Medicine Branch of the Chinese Medical Association, and the "Expert Consensus on the Clinical Application of Inhaled Nitric Oxide Therapy (2024 Edition)," led by the Respiratory Therapy Group of the Respiratory Disease Branch of the Chinese Medical Association. The release of these two expert consensus statements provides standardized recommendations for the clinical application of inhaled nitric oxide therapy in terms of indications, administration methods, equipment standards, and operational protocols.Noliving Biotech’s two nitric oxide therapy devices both meet the requirements outlined in the aforementioned consensus. They represent the only solutions that ensure synchronization with patient respiration when used in conjunction with commonly employed respiratory and life-support equipment, making this approach the preferred clinical recommendation in the expert consensus.

The successful launch of Noliving Biotech’s inaugural product has fully validated the company’s exceptional commercialization capabilities. Building on this new foundation, the company’s future development strategy will be more multidimensional and diversified.

• In terms of solutions, the company will continue to further enrich its product portfolio in critical care scenarios through in-house R&D and industrial integration;

• From the clinical application perspective, the company will continue to advance the expansion of nitric oxide (NO) gas therapy into indications such as cardiopulmonary, respiratory, immune, and anti-infective disorders;

• In consumer application scenarios, the company has recently entered into a strategic partnership with a well-known listed company and successfully launched its first general health consumer product onto the market.

Noliving Biotech incorporated overseas commercialization into its product planning from the outset. This strategic advantage stems, on one hand, from the global perspective and extensive professional networks of its founder, Dr. Mao Wen, and the core management team; on the other hand, the company’s robust technological barriers and patent moat have paved the way for its globalization. Since obtaining regulatory approval for its “Portable Inhaled Nitric Oxide (NO) Therapy Device,” the product has been successfully exported to multiple countries and regions across Asia, achieving international sales.

With the imminent approval of the EU CE (MDR) certification, the company is poised to achieve milestone breakthroughs in mature markets across Europe and the United States, as well as in the Middle East, marking a significant chapter in its global expansion strategy.

Dr. Mao Wen, Founder of Noliving BiotechNoliving Biotech stated: “Our flagship product, the nitric oxide inhalation therapy device, has been deployed in hundreds of hospitals both domestically and internationally, benefiting over 10,000 patients. In a remote county town on the border between Guangxi and Hunan provinces, our device successfully stabilized a critically ill pediatric patient on the afternoon of hospital admission. On a high-speed train traveling from Kunming to Guangzhou, our product provided life-saving support for a neonatal patient during inter-hospital transfer. Such moving cases occur daily, constantly reminding every member of Noliving Biotech of our original entrepreneurial mission. As a global medical innovation company, Noliving Biotech hopes to collaborate with more partners in promoting innovative technologies, bringing more source-innovated products that address urgent clinical needs to patients worldwide, and ensuring that an increasing number of patients receive timely and improved treatment.”

Zhou Zhou, Senior Partner at DNTcapitalIt stated: “The core team of Noliving Biotech is a group of young professionals who are mission-driven, energetic, creative, experienced, and highly effective. In just a few short years since its inception, the company has achieved remarkable milestones, including the regulatory approval and market launch of medical devices that have reached a global leading level, fully demonstrating the team’s professionalism and excellence. DNTcapital feels privileged to partner with such an outstanding team. We hope the company will uphold the principle of ‘preserving the core while stimulating progress,’ remain steadfast in its original aspiration and mission to ‘save lives,’ focus on addressing the pain points, challenges, and patient needs in clinical medical practice, and continuously develop world-class innovative products. Through these efforts to benefit both the nation and the world, the company will achieve the leap from excellence to greatness.”

Jiangsu Dingxin Capital Management Co., Ltd. (DNTcapital) is a fund management company specializing in equity investment. Established in 1998, the company was formerly known as Jiangsu Dingxin Consulting Co., Ltd., a joint venture founded by Jiangsu Kaiyuan International Group and the Jiangsu Provincial Academy of Social Sciences. Since its inception, the company has adhered to the business philosophy of “creating value through professionalism and empowering industries with capital.” Focusing on industrial transformation, technological innovation, and economic upgrading, it specializes in equity investments in fields such as biopharmaceuticals, high-end intelligent manufacturing, the digital economy, new energy and new materials, and low-carbon environmental protection. The company has accumulated extensive resources and practical experience in venture capital, mergers and acquisitions, equity investment fund management, and investment and financing consulting, while establishing a comprehensive investment management system. Committed to providing effective investment and financing management and professional advisory services to various institutions, the company identifies and integrates the potential capabilities and resources for enterprises’ rapid and healthy growth, thereby maximizing corporate value.